Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
561
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending April 2026 · Full yearPrevious forecast published 2025年６月12日付Net Sales9,283→9,944million
+7.1%
Operating profit400→961million
+140.3%
Ordinary income346→1,410million
+307.5%
Profit attributable to owners of the parent301→1,020million
+238.9%
Net income per share2.73→8.23yen
+201.5%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
米国において消化器内視鏡領域での売上が計画を上回って伸長し、営業利益の増益に貢献した。経常利益は、子会社貸付金に係る為替差損益の影響を受け、当期は円安に推移する公算が高いため為替差益が発生する見込み。
Previous-period resultsBusiness profitability 6,934 Millions of yen (yen and sen for net income per share) / Operating profit -1,156 Millions of yen (yen and sen for net income per share) / Ordinary income -2,483 Millions of yen (yen and sen for net income per share) / Profit attributable to owners of the parent -2,501 Millions of yen (yen and sen for net income per share) / Net income per share -25.2 Millions of yen (yen and sen for net income per share) / Fiscal Period Covered 2025年４月期
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥9,283 million → ¥9,944 million（+7.1%） |
| Operating profit | ¥400 million → ¥961 million（+140.3%） |
| Ordinary income | ¥346 million → ¥1,410 million（+307.5%） |
| Profit attributable to owners of the parent | ¥301 million → ¥1,020 million（+238.9%） |
| Net income per share | 2.73 yen → 8.23 yen（+201.5%） |
| Fiscal Period Covered | Fiscal year ending April 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 2025年６月12日付 |
| Previous-period results | Business profitability 6,934 Millions of yen (yen and sen for net income per share) / Operating profit -1,156 Millions of yen (yen and sen for net income per share) / Ordinary income -2,483 Millions of yen (yen and sen for net income per share) / Profit attributable to owners of the parent -2,501 Millions of yen (yen and sen for net income per share) / Net income per share -25.2 Millions of yen (yen and sen for net income per share) / Fiscal Period Covered 2025年４月期 |
| Reason for the revision | 米国において消化器内視鏡領域での売上が計画を上回って伸長し、営業利益の増益に貢献した。経常利益は、子会社貸付金に係る為替差損益の影響を受け、当期は円安に推移する公算が高いため為替差益が発生する見込み。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.米国の消化器内視鏡領域で売上が計画を上回って伸長し、営業利益に貢献したため。また、経常利益については、円安により子会社貸付金の評価額が増加し、為替差益が発生する見込みであるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.